Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles - BioSpace

[anonymous]

Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles - BioSpace

https://www.biospace.com/drug-devel...-in-doubt-as-newly-approved-drugs-hit-hurdles

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of these anti-amyloid antibodies and the amyloid hypothesis overall.​

 

[anonymous]

“These approaches have not worked,” George Perry, a neuroscientist at the University of Texas at San Antonio, told BioSpace, referring to Biogen and Eisai’s Aduhelm and Leqembi and Eli Lilly’s Kisunla. “The patients are not getting better.” Christian Hölscher, co-founder and chief scientific officer at neuroscience-focused Kariya Pharmaceuticals, agreed, raising concerns in a November interview about the drugs’ safety and efficacy profiles. “The antibodies are too toxic, and the effect in patients is so small that it is unlikely that patients even notice a difference,” he told BioSpace.

 

[anonymous]

Never. Getting. Approved.

 

[anonymous]

What, you want a therapy that might actually work and isn’t toxic? There’s no pleasing you people.

 

[anonymous]

Dirty company..l

 

[anonymous]

Never. Getting. Approved.

 

[anonymous]

None of the drugs perform better than placebo- until we do some deep dive statistics to find that it "works". So my hypothesis is that the amyloid hypothesis is junk. Many studies show patients get worse and not better. Amyloid plaque is probably more like a "scab" so you don't want to get rid of it. All that wasted $ on these drugs.

 

[anonymous]

None of the drugs perform better than placebo- until we do some deep dive statistics to find that it "works". So my hypothesis is that the amyloid hypothesis is junk. Many studies show patients get worse and not better. Amyloid plaque is probably more like a "scab" so you don't want to get rid of it. All that wasted $ on these drugs.

There are too many powerful and connected scientists and researchers in this field of research who have spent their entire adult lives on the amyloid theory - they don’t want to think they wasted their entire career chasing a dead end. Very few, except the younger ones in the field, want to admit it was a waste, a mistake to go all in on 1 theory, and after all these decades and hundreds of billions collectively spent they still don’t fundamentally understand the disease.

 

[anonymous]

None of the drugs perform better than placebo- until we do some deep dive statistics to find that it "works". So my hypothesis is that the amyloid hypothesis is junk. Many studies show patients get worse and not better. Amyloid plaque is probably more like a "scab" so you don't want to get rid of it. All that wasted $ on these drugs.

Exactly. The plaque formation is sclerotic and replaces healthy vascular tissue. Dissolving it can improve blood flow (albeit temporarily) and thus cognition, but doing that weakens the arterial wall and dramatically increases the risk of brain bleeds.

 

[anonymous]

Exactly. The plaque formation is sclerotic and replaces healthy vascular tissue. Dissolving it can improve blood flow (albeit temporarily) and thus cognition, but doing that weakens the arterial wall and dramatically increases the risk of brain bleeds.

PUMP

N

DUMP

 

[anonymous]

Never. Getting. Approved.

 

[anonymous]

Lieogen

 

[anonymous]

None of the drugs perform better than placebo- until we do some deep dive statistics to find that it "works". So my hypothesis is that the amyloid hypothesis is junk. Many studies show patients get worse and not better. Amyloid plaque is probably more like a "scab" so you don't want to get rid of it. All that wasted $ on these drugs.

We should just sell an actual placebo for $10K instead of these crap products. It couldn’t do any worse for patients and would save a crapload of money.